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A Phase II Study of ABT-751 in Patients with Advanced
Non-small Cell Lung Cancer
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Lee Schwartzberg, MD,‡ Andrew I. Coates, MD,§ Jiang Qian, PhD,§ Anne E. Hagey, MD,§
and Gary B. Gordon, MD§
Purpose: To determine the tolerability and efficacy of ABT-751, an
oral antimitotic agent that inhibits polymerization of microtubules,
in patients with advanced taxane-refractory non-small cell lung
carcinoma (NSCLC).
Patients and Methods: Eligibility was limited to patients with
recurrent or metastatic NSCLC who had received one to two
cytotoxic chemotherapy regimens, had a performance status of zero
to one, and adequate organ function. Treatment included ABT-751
200 mg daily for 21 consecutive days, followed by 7 days off drug.
Objectives were to determine response rate, time to tumor progres-
sion, survival, and tolerability of ABT-751.
Results: All 35 enrolled patients were assessable for survival,
response, and tolerability. Median time to tumor progression and
overall survival were 2.1 and 8.4 months, respectively. The objec-
tive response rate was 2.9%. One patient achieved a partial response
that was ongoing 567 days after initial documentation. Treatment
was well tolerated; fatigue, constipation, and dehydration were the
only treatment related, grade three adverse events occurring in more
than one patient. Incidence of grade 3/4 hematologic and blood
chemistry toxicities was acceptable, and ABT-751 was not associ-
ated with myelosuppression.
Conclusions: ABT-751 associated toxicity was acceptable. The
median time to progression and overall survival as demonstrated for
ABT-751 were comparable to other agents considered active in this
patient population and to current treatments approved for second-
line NSCLC. The novel antimitotic targeting of ABT-751 in com-
bination with the compound’s acceptable nonmyelosuppressive tox-
icity profile and efficacy similar to agents currently in use in this
setting, warrant further evaluation of this compound in combination
with other cytotoxic agents in advanced NSCLC.
Key Words: ABT-751, Non-small cell lung cancer, Time to tumor
progression, Response rate, Survival.
(J Thorac Oncol. 2008;3: 631–636)
Non-small cell lung carcinoma (NSCLC) comprises 80%of all lung cancers,1 which are the second most common
cancer and the leading cause of cancer mortality in the United
States. For patients with distant disease at diagnosis, the prog-
nosis is poor with a 5-year survival rate of 2%.1 Standard
treatment options for stage IV NSCLC consist of chemotherapy
and biologic therapies, whereas for stage IIIB, combination with
radiotherapy may be indicated.2,3 First-line chemotherapies in-
clude cisplatin or carboplatin in combination with paclitaxel,
docetaxel, gemcitabine, vinorelbine, or irinotecan.3,4 Approved
second-line therapies include single-agent docetaxel, pem-
etrexed, and erlotinib. None of these regimens has emerged as
superior in the second-line setting, and patients with advanced
NSCLC who have failed treatment with one or more chemo-
therapy regimens currently have limited therapeutic options.
Antimitotic agents are commonly used in the treatment
of advanced NSCLC. Three classes of antimitotic agents have
been identified. These include vinca alkaloids (e.g., vincris-
tine, vinblastine, and vinorelbine), taxanes (e.g., paclitaxel
and docetaxel), and colchicine site binders (e.g., ABT-751).
The vinca alkaloids and colchicine site binders inhibit micro-
tubule polymerization by binding to distinct sites on tubulin
-subunits,5 whereas the taxanes block depolymerization by
stabilizing microtubules.6,7 These actions block the cell cycle
at the G2/M phase resulting in the induction of apoptosis.
ABT-751 is a novel, orally bioavailable, sulfonamide
antimitotic agent, which has demonstrated antitumor ac-
tivity in vivo in syngeneic and human xenograft tumor
models of colon, lung, breast, pancreas, and bladder can-
cer.8 Antitumor activity has occurred with administration
of ABT-751 in combination with chemotherapeutic agents
such as 5-fluorouracil, cisplatin, docetaxel, and gemcitab-
ine in these respective xenograft models.8 Moreover, ABT-
751 is not a substrate for the multiple drug resistance
transporter and demonstrates activity against cell lines
resistant to vinca alkaloids and taxanes.9
ABT-751 has been evaluated in four phase I studies
in the United States and one in Japan.10–13 In both adult
and pediatric patients, ABT-751 demonstrated rapid ab-
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sorption and elimination, and dose proportional time inde-
pendent pharmacokinetics across the dose ranges studied
with minimal accumulation after multiple once daily and
twice daily doses.10,11 Common toxicities in both adult and
pediatric patients were abdominal pain, fatigue, constipa-
tion, and neuropathy.
Differences in the mechanism of antimitotic activity
between ABT-751 and the taxanes (i.e., inhibition of poly-
merization of microtubules by ABT-751 versus depolymer-
ization by taxanes) as well as its resistance to P-glycoprotein
mediated transport (which confers cellular resistance to tax-
ane therapy) suggest that ABT-751 might be of therapeutic
benefit to patients with advanced taxane refractory NSCLC.
PATIENTS AND METHODS
Patient Selection
Enrollment was limited to patients with measurable,
histologically confirmed, stage III B or stage IV NSCLC
refractory to taxane therapy. Taxane refractory was defined as
a minimum previous taxane exposure of two cycles (i.e., 6
weeks) with disease progression occurring either during tax-
ane therapy, within 12 weeks of completion of therapy in the
adjuvant setting, or within 24 weeks of completion of therapy
in the metastatic setting. Eligible patients were at least 18
years of age; had an Eastern Cooperative Oncology Group
performance status of 0 to 1; had received no more than two
prior chemotherapy regimens and no more than one investi-
gational agent, and had discontinued any prior therapy within
3 weeks of ABT-751 administration.
The protocol was approved by the Institutional Review
Boards of all participating investigational sites. Voluntary writ-
ten informed consent was obtained from all patients before
performing any study specific procedures or modifying medica-
tions to comply with the protocol.
Treatment
Outpatients self-administered ABT-751 200 mg cap-
sules by mouth once daily for 21 consecutive days, followed
by 7 days off drug (one cycle  28 days). The recommended
phase II dose was chosen based on observed preclinical
activity and Phase I maximum tolerated dose studies.10–13 In
preclinical modeling, the once daily dosing schedule demon-
strated efficacy equivalent to the twice daily dosing schedule
in Calu-6 and HT29 xenografts, as well as in the higher dose
ranges in the M0576 model. However, QD dosing of ABT-
751 was shown to be superior to the BID dosing schedule in
the M0576 model at lower doses and in the HT1376 bladder
xenograft model at all dose levels. In study M01-303, a phase
I solid tumor study, the maximum tolerated dose of 200 mg
of ABT-751 administered QD when compared with the max-
imum tolerated dose of 100 mg of ABT-751 administered
BID on a 21 of 28 day schedule demonstrated equivalent
tolerability and efficacy.
Toxicity and treatment compliance were graded at each
study visit, which occurred every 2 weeks during the first two
cycles and before the first dose for each additional cycle.
Study drug administration was held for any subject who
experienced a National Cancer Institute Common Toxicity
Criteria (NCI CTC) grade three or four toxicity that the
investigator considered possibly or probably attributable to
ABT-751 and not to the underlying disease, until the toxicity
resolved to grade 2 or lower. If a cycle was interrupted
because of toxicity, and the subject missed six or fewer doses
within the 21-day dosing period, the subject resumed the
same cycle by taking ABT-751 at a dosage reduced by 50 mg
after the toxicity resolved. If the subject missed more than six
planned doses within a cycle, that cycle was discontinued and
treatment was reinitiated when toxicity resolved with a 50 mg
dose reduction of ABT-751. If the toxicity did not resolve, the
subject was discontinued from the study drug. To assess
treatment compliance, subjects were instructed to return all
drug containers, even if empty, to the site study coordinator.
The number of capsules returned was recorded on the subject
drug accountability log.
Evaluations
Tumor assessments, based on computed tomography
scans or magnetic resonance imaging scans, were conducted
within 14 days before the initial dose of ABT-751 and
subsequently after every two cycles. Toxicities were graded
at each study visit according to the NCI CTC (version 3.0).
Toxicities not captured by the NCI CTC were categorized as
grade 1 (mild), grade 2 (moderate), grade 3/4 (severe, inca-
pacitating, or life-threatening), or grade 5 (death) by the
investigator. Hematology and chemistry laboratory tests were
performed at baseline and every 2 weeks through the first two
cycles, and on day 1 for all subsequent cycles.
Response Criteria
Tumor response and disease progression were deter-
mined using the Response Evaluation Criteria in Solid Tu-
mors (RECIST).14 Assignment of complete response (CR) or
partial response (PR) required confirmation of changes in
tumor measurements by repeat assessments performed at
least 4 weeks after the criteria for response were initially met.
Pharmacokinetic Studies
Blood samples (5 mL each) were obtained on days 1
and 15 of cycle 1 before dosing and 2 hours after dosing.
Plasma concentrations of ABT-751 and its major metabolites
were measured using a validated liquid chromatography with
tandem mass spectrometric detection methodology at Abbott
Laboratories (Abbott Park, IL).11
Statistical Methods
The primary objective of this study was to determine
the objective tumor response rate (PRs and CRs according to
RECIST) in patients with stage IIIB or IV taxane refractory
NSCLC following treatment with ABT-751. Calculation of
sample size was based on the assumption that the true
objective response rate would be 10%. Thus, with enrollment
of 30 patients, the probability that none of the 30 patients
would have an objective response was less than 5%.
Analyses of baseline patient characteristics, efficacy,
and safety were performed for all enrolled patients. The
primary efficacy end point was the objective response rate
(ORR). Secondary efficacy endpoints included the time to
tumor progression (TTP), overall survival, and the change
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from baseline to the final visit in Eastern Cooperative Oncol-
ogy Group performance status.
The ORR was defined and calculated as the percentage
of patients with a CR or PR based on RECIST criteria. The
90% confidence interval (CI) was constructed using the exact
binomial distribution.
Overall survival was calculated from the date of first
dose of ABT-751 to the date of death. All events of death
were included, regardless of whether the event occurred
while the patient was still taking study drug or after the
patient had discontinued study drug. In the absence of death,
data were censored at the date of the last study visit, the last
contact date, or the date the patient was last known to be
alive, whichever was last. Survival was assessed at 3-month
intervals after termination of ABT-751 for 2 years. Kaplan-
Meier methodology was used to determine the distributions
and 95% CIs for the median and 6- and 12-month rate
estimates of TTP and overall survival.15
Safety was assessed based on ABT-751 exposure, tox-
icities, deaths, clinical laboratory variables, and vital sign
measurements. Toxicities were summarized using the Medi-
cal Dictionary for Regulatory Activities (version 9.0), for
coding adverse events (AEs). Hematology and blood chem-
istry toxicities were assigned according to the NCI CTC
(version 3.0).
RESULTS
Patient Characteristics and Disposition
Between September 2003 and January 2006, 35 pa-
tients with taxane refractory advanced NSCLC were enrolled
in this study at 11 investigational sites. Patient characteristics
are summarized in Table 1. Before enrollment, patients had
been treated with a median of three oncology agents. The
median time from the completion of previous therapy to the
start of study drug was 40 days (range, 22–405 days). All
patients (100%) had prior taxane therapy, with 22 (63%)
receiving paclitaxel and 22 (63%) receiving docetaxel; 9
(26%) patients received both agents. Prior chemotherapy
with alkylating agents was reported by 97% (carboplatin in
32 patient [91%], cisplatin in 4 patients [11%]), antime-
tabolite therapy in 11 patients (31%), and hormones in 1
patient (3%). Nine patients (26%) progressed during tax-
ane therapy. Most patients had prior platinum therapy; 32
(91%) received carboplatin; and 4 (11%) received cispla-
tin. Ten patients (29%) had prior radiation therapy to the
lung or a site of metastatic disease.
Toxicity and Discontinuation of Study Drug
Patients discontinued the study drug, ABT-751, be-
cause of one or more of the following reasons: progressive
disease (29 [83%] as primary reason and 5 [14%] as contrib-
utory reason); AEs (13 [37%]); withdrawal of consent (3
[9%]), and other reasons (8 [23%]). One patient (3%) was lost
to follow-up. Of the patients listed with an AE as reason for
study discontinuation, 5 (14.3%) considered AE as being the
primary reason for study discontinuation, and 8 (22.9%) as a
contributory factor. Of the 5 patients who discontinued study
drug for AEs as the primary reason, the treating physician felt
the AE to be related to study drug in only 2 cases (grade 3
hallucinations and grade 1 hypotension). Additional AEs
listed as contributory reasons for study drug discontinuation
were dyspnea, muscle weakness, dizziness, neuropathy, ele-
vated mood, disorientation, constipation, dehydration, weak-
ness, cough, and malaise; of which most were deemed not
related to study drug administration. Of the 29 patients who
discontinued because of disease progression as the primary
reason, 24 met RECIST criteria and 5 discontinued based on
clinical judgment. Only one of the five patients who discon-
tinued because of disease progression as a contributory rea-
son met RECIST criteria for progressive disease.
After discontinuation from the study, 17 subjects
(48.5%) went on to receive additional therapeutic regimens
for the treatment of their progressive disease. The number of
additional therapeutic regimens ranged from 1 to 5 with 5
receiving vinorelbine, 4 given pemetrexed, 5 given gemcit-
abine, 2 given erlotonib and gefitinib, and 1 each receiving
docetaxel, capecitabine, irinotecan, triapine, carboplatin, and
halichondrin B.
Exposure to ABT-751
A median of two cycles (range, 1–26 cycles) of ABT-751
was administered, corresponding to a median duration of treat-
ment of 42 days (range, 6–546 days). Of eight patients (23%)
who received less than two cycles of treatments, 3 discontinued
because of an AE and 5 discontinued because of progressive
disease. RECIST criteria for disease progression were met for 2
TABLE 1. Patient Characteristics
Characteristic
ABT-751 (N  35)
No. Percent
Age, yr
Median 65.0
Range 29.0–84.0
Sex
Male 20 57
Female 15 43
ECOG PS
0 17 49
1 16 46
2a 2 6
Prior cytotoxic chemotherapy agents
Carboplatin 32 91
Cisplatin 4 11
Docetaxel 22 63
Gefinitib 4 11
Paclitaxel 22 63
Histology
Adenocarcinoma 10 29
Squamous cell carcinoma 10 29
Otherb 15 43
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
a Protocol originally permitted enrollment of patients with ECOG performance
status of 2. One of these two patients was enrolled after the protocol was amended to
exclude patients with ECOG performance status of 2.
b Other includes 9 patients with poorly differentiated carcinoma, 5 patients with
carcinoma, and one patient with a large cell undifferentiated tumor.
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of these 5 patients, whereas disease progression was based on
clinical assessments for the remaining 3 patients. Seven patients
(20%) received 4 cycles, 2 patients (6%) received 5 cycles, and
1 patient each (3%) received 6, 8, 10, and 26 cycles of ABT-751.
Eight patients required a single-dose reduction, and no patients
required two-dose reductions.
There were a total of 125 cycles of study drug admin-
istered to the 35 patients enrolled on trial. In 113 of the 125
total cycles administered, treating physicians noted a compli-
ance level of 80%. This was demonstrative of 90.4%
overall study drug compliance through the trial.
Efficacy
Efficacy endpoints are summarized in Table 2. One
patient (3%) achieved a PR after six cycles of treatment. The
PR was ongoing at the final tumor assessment, which was 567
days after the initial documentation of PR. A second patient
achieved tumor reduction at cycle 2 that was not confirmed
per RECIST criteria on a second scan. For this patient,
subsequent assessments of stable disease continued through
cycle 8, when disease progression occurred. Five patients
(14.3%) achieved stable disease, and progressive disease was
documented in accordance with RECIST criteria for 25 pa-
tients (71%). There were four patients (11.4%) with insuffi-
cient data to assess response due to bone only disease. The
ORR was 2.9% (90% CI, 0.15–12.85%). The disease control
rate (i.e., percentage of patients with CR  PR  stable
disease) was 14.2% through cycle 4, 9% through cycle 6, and
6% through cycle 8.
The median TTP was 2.1 month (95% CI, 1.7–3.7
months) (Figure 1). The respective 6- and 12-month TTP rate
estimates (95% CI) were 14.2% (0.0–28.4%) and 4.7% (0.0–
13.7%).
Median overall survival was 8.4 months (95% CI,
3.8–11.4 months) (Figure 2). The respective 6- and 12-month
survival rate estimates (95% CI) were 56.0% (39.4–72.7%)
and 21.9% (7.6–36.1%). Data are not sufficiently mature to
provide an estimate of survival at 2 years.
Safety and Tolerability
The most commonly experienced treatment related AEs
included fatigue (18 patients, 51%), constipation (14 patients,
40%), nausea (12 patients, 34%), and anorexia (10 patients,
29%). Treatment-related grade 3 AEs reported for more than
one patient included fatigue (6 patients, 17%) and constipa-
tion and dehydration (3 patients each, 9%). Treatment-
related, grade 4 AEs of laryngeal edema were reported for a
single patient (Table 3).
The incidence of treatment related grade 3 and 4 he-
matologic and chemistry toxicities was low. The only grade 3
hematologic toxicities that were judged related to ABT-751
were one case each of anemia and lymphopenia. Increased
blood alkaline phosphatase, which was the only grade 3 or 4
chemistry toxicity judged related to ABT-751, occurred in a
patient with grade 2 elevations in alkaline phosphatase at
baseline. All chemistry toxicities were grade 3, except for
TABLE 2. Summary of Efficacy
Endpoint
ABT-751 (N  35)
No. Percent
Response (RECIST criteria)
Complete response 0 0.0
Partial response 1 2.9
Stable disease 4 11.4
Progressive disease 25 71.4
Not evaluateda 5 14.3
Objective response rate 1 2.9
90% confidence interval (0.15–12.85)
Time to tumor progression
Median (mo) 2.1
95% CI (1.7–3.7)
RECIST, response evaluation criteria in solid tumors.
a Tumor assessments were not performed after baseline.
FIGURE 1. Kaplan-Meier plot of overall survival following
administration of ABT-751. The median overall survival was
8.4 months (95% confidence interval  3.8–11.4 months).
The respective 6- and 12-month overall survival rate esti-
mates were 56.0% (95% confidence interval  39.4–72.7%)
and 21.9% (95% confidence interval  7.6–36.1%).
FIGURE 2. Kaplan-Meier plot of time to progression follow-
ing administration of ABT-751. The median overall time to
progression was 2.1 month (95% confidence interval  1.7–
3.7 months). The respective 6- and 12-month estimates
were 14.2% (95% confidence interval  0.0–28.4%) and
4.7% (95% confidence interval  0.0–13.7%).
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hypercalcemia, which was grade 4. In most cases, the abnor-
mal hematology and chemistry values were sporadic and
resolved on subsequent testing; in some cases, however, they
were the final laboratory value so the time course of resolu-
tion remains unknown.
Deaths for 29 patients (83%) have been reported to
date. Overall, 28 patients died due to progressive NSCLC,
and one patient died because of respiratory failure 206 days
after the last dose of ABT-751.
Plasma Concentrations of ABT-751 and Its
Major Metabolites
Plasma concentrations of ABT-751, ABT-751 glucuro-
nide, and ABT-751 sulfate on days 1 and 15 are summarized
in Table 4. Plasma concentration measurements are available
for 30 patients. These results are consistent with data from 21
patients receiving ABT-751 200 mg once daily in two phase
I studies.
DISCUSSION
Treatment of patients with advanced NSCLC remains a
challenge. Chemotherapy provides limited benefit in the first-
line setting, and once disease progression occurs, median sur-
vival time is approximately 3 months. Approximately 25 to 50%
of patients with advanced NSCLC receive second-line treat-
ment.16 The median age for diagnosis is 68 years and rising,
suggesting that underlying comorbidities and use of concurrent
medications might limit the ability to administer and/or tolerate
chemotherapy.4 The limited success rate with currently available
agents highlights the need to focus on developing novel agents
that are efficacious as well as tolerable.
In this phase II study, ABT-751 administered as second-
or third-line therapy in a population of patients with advanced
NSCLC refractory taxanes demonstrated an overall survival
comparable to that of approved, marketed agents. Median over-
all survival in this study was 8.4 months, which is comparable to
median overall survival reported for docetaxel (range, 6–9
months)17–19 and pemetrexed (8.3 months) in the second-line
setting.20 ABT-751 yielded median overall survival times com-
parable to those seen in the second- or third-line setting with
erlotinib (approximately 7 months),21 and it is longer than
median overall survival seen with best supportive care or pla-
cebo (approximately 5 months) in this patient population.21,22
Progression-free survival in this study was 2.1 month, which is
similar to that seen with erlotinib (2.2 months).21 The ORR of
2.86% represented a single responder with a confirmed PR
ongoing 567 days after initial documentation. The PR was
preceded by six cycles of stable disease, suggesting that the time
to onset of response with ABT-751 may be delayed. Extended
stable disease before a documented objective response is char-
acteristic of the activity of ABT-751. Response rates for drugs
used in the second-line setting are comparable. Studies of do-
cetaxel demonstrated an ORR that ranged from 5 to 11%,17,18,20
whereas an ORR of 9% was reported for pemetrexed in one
phase III study.20 It is noteworthy that these efficacy findings for
ABT-751 were observed in a more heavily pretreated patient
population than those evaluated in studies of single-agent do-
cetaxel and pemetrexed.
ABT-751 is well tolerated and has a unique toxicity
profile noteworthy for its lack of myelosuppression. This may
be particularly advantageous in conducting combination stud-
ies with this agent. There is a need for nonmyelosuppressive
agents that can combine with other effective agents whose
dose-limiting toxicity is myelosuppression. The most com-
TABLE 3. Treatment-Related, Grade 3 and 4 Adverse
Events
Adverse Event
ABT-751 (N  35)
No. Percent
Grade 3 (Nonhematologic events)
Fatigue 6 17
Constipation 3 9
Dehydration 3 9
Asthenia 1 3
Blood alkaline phosphatase increased 1 3
Anorexia 1 3
Hypoesthesia 1 3
Peripheral motor neuropathy 1 3
Peripheral sensory neuropathy 1 3
Hallucination 1 3
Mental status changes 1 3
Grade 3 (Hematologic events)
Anemia 1 3
Lymphopenia 1 3
Grade 4a (Nonhematologic events)
Laryngeal edema 1 3
Adverse events were coded using Medical Dictionary for Regulatory Activities,
version 9.0.
a All grade 4, treatment-related adverse events were reported for the same patient.
TABLE 4. Plasma Concentrations of ABT-751 and Metabolites
Analyte
Day 1 Day 15
0 h (N  30) 2 h (N  25) 0 h 2 h (N  14)
ABT-751 (g/mL) 0.0  0.0 6.7  2.9 0.4  0.2a 6.8  2.8
ABT-751 glucuronide (g/mL) 0.0  0.0 3.4  2.3 2.2  1.4b 4.6  2.4
ABT-751 sulfate (g/mL) 0.0  0.0 5.3  3.5 2.7  1.6b 5.9  2.9
Plasma concentrations are presented as the mean  SD.
a N  18.
b N  20.
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mon AEs seen with ABT-751 reflect gastrointestinal system
disorders and general disorders. Constipation, fatigue, and
dehydration were the most frequent treatment related grade 3
AEs, whereas hematologic and blood chemistry toxicities
were uncommon. This is different from currently approved
second-line therapies, which have toxicity profiles that in-
clude myelosuppression, anemia, rash, and diarrhea.
ABT-751 pharmacokinetics in this study were consis-
tent with those observed in phase I studies.10,11 Blood sam-
ples were obtained 2 hours after dosing, which corresponds to
Tmax as determined in phase I studies. The concentrations of
ABT-751 and its metabolites measured at 2 hours after dosing
and before dosing in this study are consistent with Cmax and
Ctrough as reported previously.11 Comparison of concentra-
tions of ABT-751 and its metabolites at 2 hours after dosing
on days 1 and 15 suggest that there is no systemic accumu-
lation of drug. Clinical pharmacokinetic data suggest that a
200 mg daily dose can achieve an average steady-state area
under the curve of approximately 43 g/h/mL, which is in the
range of the projected target efficacious plasma exposure
(23–70 g/h/mL) as determined in preclinical models.
Based on its lack of myelosuppression, its mechanism
of antimitotic action with a unique binding site on -tubulin,
and the fact that it is not a substrate for the multiple drug
resistance transporter, ABT-751 is a prime candidate for the
treatment of cancer. In addition, these properties are ideal for use
in combination with other chemotherapeutic agents. Currently,
ABT-751 is being evaluated as second-line therapy in combina-
tion with docetaxel or pemetrexed in two randomized, placebo-
controlled phase II studies in patients with advanced NSCLC
and in combination with docetaxel in a study in patients with
metastatic hormone-refractory prostate cancer.
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